» Articles » PMID: 27015986

P57(Kip2) Knock-in Mouse Reveals CDK-independent Contribution in the Development of Beckwith-Wiedemann Syndrome

Overview
Journal J Pathol
Specialty Pathology
Date 2016 Mar 27
PMID 27015986
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

CDKN1C encodes the cyclin-CDK inhibitor p57(Kip2) (p57), a negative regulator of the cell cycle and putative tumour suppressor. Genetic and epigenetic alterations causing loss of p57 function are the most frequent cause of Beckwith-Wiedemann syndrome (BWS), a genetic disorder characterized by multiple developmental anomalies and increased susceptibility to tumour development during childhood. So far, BWS development has been attributed entirely to the deregulation of proliferation caused by loss of p57-mediated CDK inhibition. However, a fraction of BWS patients have point mutations in CDKN1C located outside of the CDK inhibitory region, suggesting the involvement of other parts of the protein in the disease. To test this possibility, we generated knock-in mice deficient for p57-mediated cyclin-CDK inhibition (p57(CK) (-) ), the only clearly defined function of p57. Comparative analysis of p57(CK) (-) and p57(KO) mice provided clear evidence for CDK-independent roles of p57 and revealed that BWS is not caused entirely by CDK deregulation, as several features of BWS are caused by the loss of CDK-independent roles of p57. Thus, while the genetic origin of BWS is well understood, our results underscore that the underlying molecular mechanisms remain largely unclear. To probe these mechanisms further, we determined the p57 interactome. Several partners identified are involved in genetic disorders with features resembling those caused by CDKN1C mutation, suggesting that they could be involved in BWS pathogenesis and revealing a possible connection between seemingly distinct syndromes. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Citing Articles

p57 Phosphorylation Modulates Its Localization, Stability, and Interactions.

Stampone E, Bencivenga D, Dassi L, Sarnelli S, Campagnolo L, Lacconi V Int J Mol Sci. 2024; 25(20).

PMID: 39456957 PMC: 11508627. DOI: 10.3390/ijms252011176.


STK40 inhibits trophoblast fusion by mediating COP1 ubiquitination to degrade P57.

Li X, Shao L, Li Z, Wang Y, Cai Q, Wang S J Transl Med. 2024; 22(1):852.

PMID: 39304928 PMC: 11414097. DOI: 10.1186/s12967-024-05360-y.


miR-92b-3p Regulates Cell Cycle and Apoptosis by Targeting , Thereby Affecting the Sensitivity of Colorectal Cancer Cells to Chemotherapeutic Drugs.

Zhao F, Yang Z, Gu X, Feng L, Xu M, Zhang X Cancers (Basel). 2021; 13(13).

PMID: 34283053 PMC: 8268555. DOI: 10.3390/cancers13133323.


Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57.

Kullmann M, Pegka F, Ploner C, Hengst L Front Cell Dev Biol. 2021; 9:664609.

PMID: 33928088 PMC: 8076676. DOI: 10.3389/fcell.2021.664609.


Functional Versatility of the CDK Inhibitor p57.

Creff J, Besson A Front Cell Dev Biol. 2020; 8:584590.

PMID: 33117811 PMC: 7575724. DOI: 10.3389/fcell.2020.584590.